Therapeutics News and Research

RSS

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's portfolio of NaP2b inhibitors effective September 30, 2015.

2 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Gene therapy restores visual function in mouse model of LCA1

Mice lacking the protein retGC1, which is deficient in humans suffering Leber congenital amaurosis-1 (LCA1), a disorder that causes severe visual impairment beginning in infancy, received gene therapy to replace retGC1 and showed fully restored visual function that persisted for at least 6 months.

1 Sep 2015

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Abbott (NYSE: ABT) announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

1 Sep 2015

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that its BNC101 IND submission has passed review by the US Food and Drug Administration (FDA).

31 Aug 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

CytomX announces filing of registration statement for proposed initial public offering of common stock

CytomX Therapeutics, Inc., a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.

29 Aug 2015

Synthetic tissue environment enables spatial definition of cancer cells and macrophages

Tumors are notoriously difficult to study in their natural habitat - body tissues - but a new synthetic tissue environment may give cancer researchers the next-best look at tumor growth and behavior.

29 Aug 2015

Four UC San Diego researchers selected to receive newly established NCI Outstanding Investigator Award

Four University of California, San Diego School of Medicine researchers have been selected to receive the newly established National Cancer Institute (NCI) Outstanding Investigator Award. The multi-million dollar awards fund new projects that have an unusual potential in cancer research over seven years.

29 Aug 2015

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Telesta Therapeutics Inc. announced today that it has received its BLA Filing Notification for MCNA from the U.S. Food and Drug Administration. This formal letter communicates that the FDA has completed its initial review of Telesta's Biologics License Application (BLA) submitted on June 29, 2015 and has accepted it for filing.

29 Aug 2015

Researchers provide new insights into biology of aging, age-related diseases

The scientific team of a new biotech company Gero in collaboration with one of the leading academics in the field of aging Prof. Robert J. Shmookler Reis (current world record holder in life extension for model animals - 10 fold for nematodes) has recently brought new insights into biology of aging and age-related diseases, primarily, around the stability and stress resistance of certain gene regulatory networks.

28 Aug 2015

Research: Mechanisms behind bacterial warfare could be harnessed to target pathogenic bacteria

Two UC Santa Barbara graduate students have demonstrated how certain microbes exploit proteins in nearby bacteria to deliver toxins and kill them.

28 Aug 2015

Brainbow technique reveals surprising data about brain's visual circuitry

Neuroscientists know that some connections in the brain are pruned through neural development. Function gives rise to structure, according to the textbooks. But scientists at the Virginia Tech Carilion Research Institute have discovered that the textbooks might be wrong.

28 Aug 2015

University of Nottingham to lead £6.5m research project that aims to develop next generation biomaterials

The University of Nottingham is to lead a £6.5m research project which aims to make the leap from 2D to 3D in the development of advanced materials and realise the true potential of regenerative medicine and medical devices for the future.

27 Aug 2015

Researchers design online database to help researchers identify cancer gene mutations

Many clinical trials use genome sequencing to learn which gene mutations are present in a patient's tumor cells. The question is important because targeting the right mutations with the right drugs can stop cancer in its tracks. But it can be difficult to determine whether there is evidence in the medical literature that particular mutations might drive cancer growth and could be targeted by therapy, and which mutations are of no consequence.

27 Aug 2015

Cryoport to support future clinical trials for Opexa's personalized T-cell immunotherapy programs for MS, NMO

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, today announced that its validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' lead personalized T-cell immunotherapy programs for Multiple Sclerosis ("MS") and Neuromyelitis Optica ("NMO").

27 Aug 2015

Experts shed light on the exciting field of therapy research for inflammatory diseases

What is happening in the treatment research of the inflammatory autoimmune diseases? Experts from several fields of medicine shed their light on the exciting field of therapy research for the inflammatory (autoimmune) diseases.

27 Aug 2015

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Platform therapeutic company Symic Biomedical, Inc. announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.

27 Aug 2015

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended June 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

27 Aug 2015

Study shows that quitting smoking after heart attack improves mental health, quality of daily life

A new study shows that quitting smoking after a heart attack has immediate benefits, including less chest pain, better quality of daily life and improved mental health. Many of these improvements became apparent as little as one month after quitting and are more pronounced after one year, according to the research at Washington University School of Medicine in St. Louis.

26 Aug 2015

Therapeutics News and Research

Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Gene therapy restores visual function in mouse model of LCA1

Abbott reports positive results of ABSORB Japan study comparing efficacy of fully dissolving heart stent to XIENCE

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

CytomX announces filing of registration statement for proposed initial public offering of common stock

Synthetic tissue environment enables spatial definition of cancer cells and macrophages

Four UC San Diego researchers selected to receive newly established NCI Outstanding Investigator Award

Telesta Therapeutics receives FDA BLA Filing Notification for MCNA

Researchers provide new insights into biology of aging, age-related diseases

Research: Mechanisms behind bacterial warfare could be harnessed to target pathogenic bacteria

Brainbow technique reveals surprising data about brain's visual circuitry

University of Nottingham to lead £6.5m research project that aims to develop next generation biomaterials

Researchers design online database to help researchers identify cancer gene mutations

Cryoport to support future clinical trials for Opexa's personalized T-cell immunotherapy programs for MS, NMO

Experts shed light on the exciting field of therapy research for inflammatory diseases

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

Study shows that quitting smoking after heart attack improves mental health, quality of daily life

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News